FDA Panel Disapproves Of HIFU For Prostate Cancer
HIFU, which has been used in other countries for about 15 years, is marketed in Europe by EDAP TMS, a French company operating in the US as EDAP Technology. This robotic technology would be the first device of its kind to get approved in the USA.
HIFU consists of a treatment module designed to connect a control console to an endorectal probe device. After the patient has been anaesthetised, a urologist robotically controls the probe for insertion into the rectum, enabling the device to deliver ultrasonic energy to a focused portion of the prostate. In the process, high-intensity waves from an ultrasound imaging transducer in the probe generate intensive heat (85-95C). This causes ablation of cancerous tissue while preserving the apex, sphincter, and rectum, according to EDAP.
However, the Gastroenterology and Urology Panel of the FDA's Medical Devices Advisory Committee expressed concerns about the paucity of data available from HIFU sponsor's research findings that were presented as part of its US premarket approval application.
A majority of panel members voted 'No' to the question regarding a reasonable assurance that the therapy is safe. In addition, panel members voted unanimously against reasonable assurance that the treatment is effective.
During the hearing, EDAP presenters emphasised the "body of evidence" strongly supports the approval of HIFU in the US. The benefits of a noninvasive and localised therapy with exact energy delivery, they said, outweigh the risks for urinary obstructive morbidity. The side effects from HIFU are "not dissimilar" to those caused by other prostate cancer treatments, including radiation therapy, EDAP pointed out.
FDA presenters, however, reviewed EDAP's submission documents carefully, citing these deficiencies: lack of data and safety concerns (ie, a 28% cumulative positive biopsy rate two years after HIFU treatment among participants in a nonrandomised trial).
Inderbir Gill, MD, chair of the University of Southern California, Los Angeles, Institute of Urology, is among those who support the HIFU treatment. HIFU may not be perfect but all ablation technologies have similar biopsy rates, Dr. Gill told panel members. "It's about patient choice."
HIFU has been used in 40,000 patients during a 15-year period, said Dr. Gill, adding that the device has never been suspended or withdrawn from the market.
Image credit: Harvard Medical School
Published on : Tue, 5 Aug 2014
Print as PDF
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
The TE7 touch screen ultrasound system is designed to provide superior quality imaging for rapid patient-care decisions. Intuitive gesture controls and efficient focused point-of-care exams minimize the user learning curve, with no need to navigate a...
Sectra PACS is designed for a high production environment with stability and usability in focus. Highlights include functions to speed up oncology workflows such as anatomical linking and support for reviewing complex multiparametric MRI studies such...
Powered by the most revolutionary ZONE Sonography® Technology, Resona 7’s new ZST+ platform brings the ultrasound image quality to a higher level by zone acquisition and channel data processing. Resona 7 also provides clinical research with the revolutionary...
Sectra's reporting module, developed with complex oncology cases in mind, facilitates overview of relevant priors together with the current request and report text. It also offers support for resident workflows and embedded links to images in the rep...